Biomea Fusion (BMEA) Stock Price, News & Analysis

Company Overview

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Key Stats

• Today's Range: $8.37 to $8.76
• 50-Day Range: $5.04 to $8.71
• 52-Week Range: $3.61 to $22.74
• Volume: 419,386 shs
• Average Volume: 1.03 million shs
• Market Capitalization: $310.56 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.33
• Consensus Rating: Moderate Buy

Biomea Fusion Stock Analysis - MarketRank™

Biomea Fusion scored higher than 49% of companies evaluated by MarketBeat, and ranked 599th out of 1,006 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Biomea Fusion has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Biomea Fusion has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Biomea Fusion are expected to grow in the coming year, from ($4.09) to ($3.33) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Biomea Fusion is -2.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biomea Fusion is -2.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Biomea Fusion has a P/B Ratio of 1.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

27.48% of the float of Biomea Fusion has been sold short.

Short Interest Ratio / Days to Cover

Biomea Fusion has a short interest ratio ("days to cover") of 6.9.

Change versus previous month

Short interest in Biomea Fusion has recently increased by 7.84%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biomea Fusion does not currently pay a dividend.

Dividend Growth

Biomea Fusion does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

27.48% of the float of Biomea Fusion has been sold short.

Short Interest Ratio / Days to Cover

Biomea Fusion has a short interest ratio ("days to cover") of 6.9.

Change versus previous month

Short interest in Biomea Fusion has recently increased by 7.84%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: N/A

News Sentiment

Biomea Fusion has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Biomea Fusion this week, compared to 3 articles on an average week.

Search Interest

Only 3 people have searched for BMEA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

2 people have added Biomea Fusion to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biomea Fusion insiders have not sold or bought any company stock.

Percentage Held by Insiders

27.57% of the stock of Biomea Fusion is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

96.72% of the stock of Biomea Fusion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BMEA Stock Analysis - Frequently Asked Questions

How have BMEA shares performed this year?

Biomea Fusion's stock was trading at $14.52 on January 1st, 2024. Since then, BMEA stock has decreased by 40.5% and is now trading at $8.64.
View the best growth stocks for 2024 here.

How were Biomea Fusion's earnings last quarter?

Biomea Fusion, Inc. (NASDAQ:BMEA) posted its earnings results on Wednesday, July, 31st. The company reported ($1.03) EPS for the quarter, hitting the consensus estimate of ($1.03).

When did Biomea Fusion IPO?

Biomea Fusion (BMEA) raised $120 million in an IPO on Friday, April 16th 2021. The company issued 7,500,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Piper Sandler acted as the underwriters for the IPO.

Who are Biomea Fusion's major shareholders?

Biomea Fusion's top institutional shareholders include Renaissance Technologies LLC (0.92%), Sculptor Capital LP, Bank of New York Mellon Corp (0.26%) and SG Americas Securities LLC (0.16%). Insiders that own company stock include Bihua Chen, A2a Pharmaceuticals, Inc, Michael JM Hitchcock and Franco Valle.
View institutional ownership trends.

How do I buy shares of Biomea Fusion?

Shares of BMEA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Last Earnings: 7/31/2024
• Today: 9/20/2024
• Next Earnings (Estimated): 11/04/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BMEA
• CUSIP: N/A
• CIK: 1840439
• Web: www.biomeafusion.com
• Phone: 650-980-9099
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $25.33
• High Stock Price Target: $60.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +189.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.57)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-117,250,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -91.86%
• Return on Assets: -76.56%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.62
• Quick Ratio: 4.62

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.74 per share
• Price / Book: 1.84

Miscellaneous

• Outstanding Shares: 35,945,000
• Free Float: 26,035,000
• Market Cap: $314.16 million
• Optionable: Optionable
• Beta: -0.47